Literature DB >> 9687378

Plasma lipoprotein distribution of liposomal nystatin is influenced by protein content of high-density lipoproteins.

S M Cassidy1, F W Strobel, K M Wasan.   

Abstract

The plasma lipoprotein distribution of free nystatin (Nys) and liposomal nystatin (L-Nys) in human plasma samples with various lipoprotein lipid and protein concentrations and compositions was investigated. To assess the lipoprotein distributions of Nys and L-Nys, human plasma was incubated with Nys and L-Nys (equivalent to 20 microg/ml) for 5 min at 37 degreesC. The plasma was subsequently partitioned into its lipoprotein and lipoprotein-deficient plasma fractions by step-gradient ultracentrifugation, and each fraction was analyzed for Nys content by high-pressure liquid chromatography. The lipid and protein contents and compositions of each fraction were determined with enzymatic kits. Following the incubation of Nys and L-Nys in human plasma the majority of Nys recovered within the lipoprotein fractions was recovered from the high-density lipoprotein (HDL) fraction. Incorporation of Nys into liposomes consisting of dimyristoylphosphatidylcholine and dimyristoylphosphatidylglycerol significantly increased the percentage of drug recovered within the HDL fraction. Furthermore, it was observed that as the amount of HDL protein decreased the amounts of Nys and L-Nys recovered within this fraction decreased. These findings suggest that the preferential distribution of Nys and L-Nys into plasma HDL may be a function of the HDL protein concentration.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9687378      PMCID: PMC105704          DOI: 10.1128/AAC.42.8.1878

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  The in vitro transfer of [14C]dimyristoylphosphatidylcholine from liposomes to subfractions of human plasma high density lipoproteins as resolved by isoelectric focusing.

Authors:  J Damen; M Waite; G Scherphof
Journal:  FEBS Lett       Date:  1979-09-01       Impact factor: 4.124

2.  Differences in lipoprotein concentration and composition modify the plasma distribution of free and liposomal annamycin.

Authors:  K M Wasan; R E Morton
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

3.  Human apolipoprotein A-I forms thermally stable complexes with anionic but not with zwitterionic phospholipids.

Authors:  W K Surewicz; R M Epand; H J Pownall; S W Hui
Journal:  J Biol Chem       Date:  1986-12-05       Impact factor: 5.157

4.  Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats.

Authors:  K M Wasan; K Vadiei; G Lopez-Berestein; D R Luke
Journal:  J Infect Dis       Date:  1990-03       Impact factor: 5.226

5.  Liposomes as carriers of antifungal drugs.

Authors:  G Lopez-Berestein
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

Review 6.  Plasma protein binding and therapeutic drug monitoring.

Authors:  M Rowland
Journal:  Ther Drug Monit       Date:  1980       Impact factor: 3.681

7.  Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B.

Authors:  G Lopez-Berestein; R Mehta; R L Hopfer; K Mills; L Kasi; K Mehta; V Fainstein; M Luna; E M Hersh; R Juliano
Journal:  J Infect Dis       Date:  1983-05       Impact factor: 5.226

8.  Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B.

Authors:  K M Wasan; M G Rosenblum; L Cheung; G Lopez-Berestein
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

9.  Distribution of free and liposomal annamycin within human plasma is regulated by plasma triglyceride concentrations but not by lipid transfer protein.

Authors:  K M Wasan; R Perez-Soler
Journal:  J Pharm Sci       Date:  1995-09       Impact factor: 3.534

10.  Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice.

Authors:  G Lopez-Berestein; R L Hopfer; R Mehta; K Mehta; E M Hersh; R L Juliano
Journal:  J Infect Dis       Date:  1984-08       Impact factor: 5.226

View more
  11 in total

1.  Lipoprotein distribution of a novel endotoxin antagonist, E5531, in plasma from human subjects with various lipid levels.

Authors:  K M Wasan; F W Strobel; S C Parrott; M Lynn; W J Christ; L D Hawkins; D P Rossignol
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

2.  A comparison of step-gradient and sequential density ultracentrifugation and the use of lipoprotein deficient plasma controls in determining the plasma lipoprotein distribution of lipid-associated nystatin and cyclosporine.

Authors:  K M Wasan; S M Cassidy; M Ramaswamy; A Kennedy; F W Strobel; S P Ng; T Y Lee
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

Review 3.  Human pharmacogenomic variations and their implications for antifungal efficacy.

Authors:  Joseph Meletiadis; Stephen Chanock; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

4.  Plasma protein distribution and its impact on pharmacokinetics of liposomal amphotericin B in paediatric patients with malignant diseases.

Authors:  Ying Hong; Peter J Shaw; Bruce N Tattam; Christa E Nath; John W Earl; Katherine R Stephen; Andrew J McLachlan
Journal:  Eur J Clin Pharmacol       Date:  2006-12-19       Impact factor: 2.953

5.  Species differences in the proportion of plasma lipoprotein lipid carried by high-density lipoproteins influence the distribution of free and liposomal nystatin in human, dog, and rat plasma.

Authors:  M Ramaswamy; T L Wallace; P A Cossum; K M Wasan
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

6.  Role of phospholipid transfer protein on the plasma distribution of amphotericin B following the incubation of different amphotericin B formulations.

Authors:  Nilesh Patankar; Kishor M Wasan
Journal:  Pharm Res       Date:  2006-05-10       Impact factor: 4.200

7.  Modifications in lipoprotein surface charge alter cyclosporine A association with low-density lipoproteins.

Authors:  Kishor M Wasan; Olena Sivak
Journal:  Pharm Res       Date:  2003-01       Impact factor: 4.200

8.  Differences in the lipoprotein distribution of free and liposome-associated all-trans-retinoic acid in human, dog, and rat plasma are due to variations in lipoprotein lipid and protein content.

Authors:  K M Wasan; M Ramaswamy; S P Ng; W Wong; S C Parrott; J O Ojwang; T Wallace; P A Cossum
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

9.  Distribution of brevetoxin (PbTx-3) in mouse plasma: association with high-density lipoproteins.

Authors:  Ricky T Woofter; Page C Spiess; John S Ramsdell
Journal:  Environ Health Perspect       Date:  2005-11       Impact factor: 9.031

10.  Conjugation of squalene to gemcitabine as unique approach exploiting endogenous lipoproteins for drug delivery.

Authors:  Dunja Sobot; Simona Mura; Semen O Yesylevskyy; Laura Dalbin; Fanny Cayre; Guillaume Bort; Julie Mougin; Didier Desmaële; Sinda Lepetre-Mouelhi; Grégory Pieters; Bohdan Andreiuk; Andrey S Klymchenko; Jean-Louis Paul; Christophe Ramseyer; Patrick Couvreur
Journal:  Nat Commun       Date:  2017-05-30       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.